Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M701 intraperitoneal infusion vs intraperitoneal chemotherapy for malignant ascites
CTR20211787Phase 2Completed
- Sponsor
- Wuhan YZY Biopharma Co., Ltd.
- Start
- Jul 2021
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of M701 in malignant ascites, gastric cancer (GC), colorectal cancer (CRC), ovarian cancer, primary peritoneal cancer (PPC), sponsored by Wuhan YZY Biopharma Co., Ltd.. Started Jul 2021; status: completed.
02
Drugs
M701
03
Conditions
malignant ascitesgastric cancer (GC)colorectal cancer (CRC)ovarian cancerprimary peritoneal cancer (PPC)
Beyond the preview
Go deeper on CTR20211787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211787.